Answers are grounded in this paper and cite their sources.
Background Optimal salvage therapy for non-HIV-infected immunocompromised adults with progressive Pneumocystis jirovecii pneumonia (PJP) failing first-line trimethoprim–sulfamethoxazole (TMP-SMX) remains undefined. Caspofungin plus TMP-SMX has emerged as a potential salvage option through dual inhibition of β-1,3-D-glucan synthesis in cysts and folate synthesis in trophozoites. However, comparative data against clindamycin plus primaquine are lacking. Study design and methods This retrospective cohort included non-HIV-infected immunocompromised adults with proven/probable PJP who developed clinical failure after at least 5 days of TMP-SMX treatment (defined as absence of clinical improvement accompanied by respiratory deterioration requiring escalation of oxygen support) and received salvage therapy with either caspofungin plus TMP-SMX (caspofungin group) or clindamycin plus primaquine (C-P group). The primary outcome was 28-day all-cause mortality. Results Of 41 patients, 19 were in the caspofungin group and 22 in the C-P group. Baseline SOFA-2 scores and respiratory support at salvage initiation were comparable. The 28-day mortality rate was 47.4% (95% CI, 27.3–68.3%) in the caspofungin group versus 54.5% (95% CI, 34.7–73.1%) in the C-P group (P = 0.758). The 90-day mortality also did not differ significantly (47.4% vs. 59.1%; P = 0.538). After adjusting for invasive mechanical ventilation and bacterial coinfection in multivariable analysis, the salvage regimen was not an independent predictor of 28-day mortality (OR, 0.872; 95% CI, 0.202 - 3.475; P = 0.852). No adverse events were specifically attributed to caspofungin. In the C-P group, methemoglobinemia was detected on arterial blood gas analysis in 81.8% of patients (18/22); 10 patients had methemoglobin levels >10% and 5 required methylene blue administration and/or primaquine discontinuation. Conclusion In this small retrospective cohort, mortality did not differ significantly between the two salvage strategies. Methemoglobin elevation was frequent during clindamycin–primaquine treatment, whereas no caspofungin-attributed adverse events were recorded. Given the exploratory design, these findings should not be interpreted as evidence of therapeutic equivalence or a safety advantage for either regimen.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: